A phase I study of oral ixabepilone in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 5, 2014, Pages 1071-1078

  Deeken, John F ^a   Marshall, John L ^a   Pishvaian, Michael J ^b   Hwang, Jimmy ^b   Ahlers, Christoph M ^c   Clemens, Pamela L ^c   Parker, Susan M ^c   Iacono, Lisa ^c   LoRusso, Patricia M ^d  

^a Inova Comprehensive Cancer and Research Center   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Advanced solid tumors; Ixabepilone; Oral; Pharmacokinetics

Indexed keywords

FAMOTIDINE; IXABEPILONE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOSE LIMITING TOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOXICITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; ILEUS; LEUKOPENIA; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMACH PH; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; EPOTHILONES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84900810286     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2443-7     Document Type: Article

References (12)

1. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217 (Pubitemid 350232252)
2. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, de Mendoza FH, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH (2010) Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 122:409-418. doi:10.1007/s10549-010-0901-4
3. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:3256-3263. doi:10.1200/JCO.2009.24. 4244
4. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN (2007) Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414 (Pubitemid 47310876)
5. IXEMPRA™ Kit (ixabepilone) for injection (2011). Prescribing information. Bristol-Myers Squibb Company, Princeton. http://packageinserts.bms. com/pi/pi-ixempra.pdf
6. Data on file. An exploratory study of ixabepilone administered as an enteric coated formulation to patients with advanced cancer. CA163088 final clinical study report. Bristol-Myers Squibb, Princeton
7. Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL (2012) Phase I trial of ixabepilone administered as three oral doses each separated by 6 h every 3 weeks in patients with advanced solid tumors. Investig New Drugs 30:2364-2370. doi:10.1007/s10637-012-9800-3
8. Gadgeel SM, Wozniak A, Boinpally R, Wiegand R, Heilbrun LK, Jain V, Parchment R, Colevas D, Cohen MB, LoRusso PM (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 11:6233-6239 (Pubitemid 41262953)
9. Halfdanarson TR, Jatoi A (2010) Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Curr Oncol Rep 12:247-252. doi:10.1007/s11912-010-0103-6
10. Aisner J (2007) Overview of the changing paradigm of cancer treatment: oral chemotherapy. Am J Health Syst Pharm 64(Suppl 5):S4-S7
11. Schellens JH (2005) Challenges of oral chemotherapy. Clin Adv Hematol Oncol 3:99-100
12. Ratain MJ, Cohen E (2007) The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 25:3397-3398 (Pubitemid 47310874)